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The ability to reprogram adult somatic cells back to pluripotency presents a powerful tool for studying cell-
fate identity and modeling human disease. However, the reversal of cellular age during reprogramming
results in an embryonic-like state of induced pluripotent stem cells (iPSCs) and their derivatives, which pre-
sents specific challenges for modeling late onset disease. This age reset requires novel methods to mimic
age-related changes but also offers opportunities for studying cellular rejuvenation in real time. Here, we
discuss how iPSC research may transform studies of aging and enable the precise programming of cellular
age in parallel to cell-fate specification.Pluripotent stem cells (PSCs) are characterized by their ability to
extensively self-renew and differentiate into all the cell types of
the body. During normal development, human pluripotency is
restricted to the earliest stages of somatic and germ cell devel-
opment, stages that can be captured in human embryonic
stem cells (ESCs) (Thomson et al., 1998) and embryonic germ
cells (EGCs) (Shamblott et al., 1998). The discovery of induced
PSCs (iPSCs) (Takahashi et al., 2007; Takahashi and Yamanaka,
2006; Yu et al., 2007) was the realization of a longstanding dream
in biology, namely to access pluripotency starting from somatic
cells of an adult organism. Human iPSC technology has opened
up new frontiers in regenerative medicine and human disease
modeling. Protocols for the directed differentiation of human
PSCs (hPSCs) have been developed to generate an increasingly
broad repertoire of differentiated human lineages, and a future is
foreseeable wherein any human cell type can be generated
in vitro—on demand and at scale. Although technologies for
the programming and reprogramming of cell fate have evolved
rapidly, our ability to control the maturation state and age of re-
sulting pluripotent-derived lineages remains rudimentary at best.
In fact, there is general agreement that human-pluripotent-
derived lineages exhibit the properties of fetal-stage cells such
as in the case of hPSC-derived neural, cardiac, or pancreatic lin-
eages. Importantly, such fetal-like properties are observed in
iPSC-derived lineages independent of the age of the initial so-
matic cell donor. The embryonic-like nature of hPSC-derivatives
represents a potential barrier to the use of PSCs, which moti-
vates the development of strategies for directing cellular age
in vitro, in particular for applications in human disease modeling.
On the other hand, those findings raise the intriguing question
whether the reprogramming process resets not only cell fate
(i.e., from specified to pluripotent) but also the chronological
age characteristic of the donor cell population.
Here, we will discuss recent studies that address questions of
age in pluripotent stem cells. Those include both efforts to study
the apparent rejuvenation process during reprogramming aswell
as the development of techniques to artificially induce age in
iPSC-derived lineages for modeling late-onset disorders. The
long-term goal is to reliably program and re-program cellular
age independently of cell fate and thereby recrate specific celltypes of any age (e.g., 80-year-old neurons, 20-year-old pancre-
atic cells, or 40-year-old heart cells).
Current Strategies for Studying Aging
According to the World Health Organization, global life expec-
tancy will increase from 48 years of age in 1950 to 73 years
by 2025 (http://www.who.int/whr/1998/en/whr98_en.pdf?ua=1),
and, in many developed countries, the average life expectancy
is already >80 years and rising. The associated worldwide in-
crease in the incidence of age-related disorders such as
Alzheimer’s (AD) and Parkinson’s disease (PD) is expected to
cause enormous social, economic, and medical challenges. The
mounting problem of an aging society has triggered a race to
find novel strategies to treat age-related disorders. Amore radical
proposition is the search of the ‘‘youth elixir,’’ hence the develop-
ment of techniques that would actively rejuvenate the human
body. However, if such strategies were to succeed, they would
likely further extend overall human lifespan with unknown conse-
quences for society. In fact, the pursuit of preventing human ag-
ing has been touted by some as ‘‘egocentric efforts of rich people
to live longer’’ (http://www.reddit.com/r/IAmA/comments/2tzjp7/
hi_reddit_im_bill_gates_and_im_back_for_my_third/). On the
other hand, anyone who has witnessed the suffering of loved
ones can understand the motivation for treating or even better
preventing serious age-related disorders and achieving longer
and healthier lives. Independently of whether such efforts are
considered as ‘‘chasing immortality’’ or simply as addressing
the emerging challenge of potentially billions of elderly people
facing aging-related consequences, the question of age and
longevity is a fascinating scientific problem. The main challenge
for tackling this issue is the identification of a unanimously
accepted cause of aging.
Modern theories of aging can be classified into programmed
versus damage or error-induced mechanisms. Theories of
programmed aging argue for a developmentally controlled pro-
gram that drives aging through the regulation of tissue homeo-
stasis as well as repair and defense responses. In contrast,
damage- or error-induced aging theories emphasize the tem-
poral or stress-induced accumulation of damage caused by
reactive oxygen species (ROS), cross-linked macromolecules,Cell Stem Cell 16, June 4, 2015 ª2015 Elsevier Inc. 591
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Figure 1. Traditional Approaches and Cellular Hallmarks of Aging
(A) Screens in model organisms were crucial for the identification of signaling pathways that increase organismal lifespan. Such pathways include insulin/IGF1
signaling (IIS) and nutrient-sensing pathways among others. An alternative strategy is focused on the identification of genomic determinants of longevity through
the study of exceptionally long-lived or short-lived animals. Organisms with unusually long lifespans include the naked mole rat, the bowhead whale, or the
Brandt’s bat. Examples of short-lived animals of interest in aging research include the killifish and hydra.
(B) Heterochronic parabiosis has become an important tool for the discovery of systemic factors capable of restoring a youthful regenerative capacity in aged
tissues through shared blood circulation with a young animal. Blood-borne factors capable of mediating the effects of parabiosis have been identified including
factors promoting skeletal muscle, blood vessel, brain, and heart regeneration.
(C) An additional approach to study aging represents the investigation of cellular alterations that accompany organismal aging. Cellular hallmarks of age that can
be readily measured can affect virtually any compartment of the cell. Additional hallmarks such as altered intracellular communication and defects in nutrient
sensing are not shown here because they are difficult to quantify in vitro.
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drivers. Aging has also been explained by some as direct
consequence of the ‘‘intrinsic thermodynamic instability of
most complex biological molecules’’ (Hayflick, 2007) leading
to progressive loss of molecular fidelity. Although multiple
mechanisms most likely contribute to the aging process,
consensus on the key molecular and biochemical cause
of organismal aging remains elusive (Jin, 2010; Liu et al.,
2012a).
Various approaches have been proposed for studying and
manipulating the rate of aging. Traditionally, those have
included the use of model organisms that enable pharmacolog-
ical and genetic screens for lifespan extension and the search
for systemic factors able to promote regenerative responses
aimed at repairing age-dependent tissue damage. Several
questions are raised by these studies, such as whether pro-
longed lifespan and improved systemic fitness are reflective
of a reversal of organismal age at the level of tissues and single
cells or whether enhanced longevity and regeneration can
occur independently of a true reset of cellular age. Further-
more, it remains unclear whether the manifestations of organ-
ismal aging at the levels of organs and tissues are directly
correlated to aging hallmarks that can be measured at the level
of individual cells.592 Cell Stem Cell 16, June 4, 2015 ª2015 Elsevier Inc.Longevity Pathways in Model Organisms
To gain insight into the molecular mechanisms of aging, a major
focus has been set on genetically tractable model organisms
such as yeast, worms, and flies, which allow the direct testing
of the impact of genetic or pharmacological interventions on
overall lifespan (Guarente and Kenyon, 2000) (Figure 1A). Ge-
netic screens in invertebrates and subsequent studies in mam-
mals have identified the insulin/IGF1 signaling (IIS) pathway,
and the equivalent mammalian somatotrophic axis as the most
evolutionarily conserved longevity-controlling pathway. In fact,
every component of the IIS pathway that connects nutrient
sensing to gene-regulatory mechanisms was shown to directly
affect organismal lifespan. These factors comprise, aside from
the insulin/IGF-1 receptor and its downstream effectors, other
nutrient-sensing regulators, such as mTOR, AMPK, and sirtuins
(Kenyon, 2010). Interfering with the IIS pathway is believed to
mimic the low-energy state brought about by caloric restriction
(CR), currently the most robust intervention known to prolong
lifespan across species. CR involves a reduction of food intake
while avoiding malnutrition and is associated with lower IIS
signaling. This regime was shown to extend lifespan, improve
stem cell-based regeneration, and delay the onset of age-related
diseases such as cancer, diabetes or neurodegenerative dis-
ease, thereby prolonging the so called ‘‘healthspan’’ (Cerletti
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2010; Mattison et al., 2012). Consistent with the effect of low
nutrient intake on longevity, genetic screens in the worm demon-
strated that loss of function of the insulin receptor daf-2 can lead
to a dramatic extension of lifespan that is dependent on the ac-
tivity of the FOXO forkhead transcription factor daf-16. Further-
more, combining daf-2 loss of function with the removal of repro-
ductive organs yields an astonishing increase in worm lifespan
up to 6-fold from 20 days to over 120 days (Arantes-Oliveira
et al., 2003).
Studies in yeast were first to identify sirtuins as major pro-
longevity factors. Sirtuins are NAD+-dependent deacylases
and mono-ADP-ribosyl transferases and serve as nutrient sen-
sors that link metabolic changes to stress response and epige-
netic regulation. Sirtuins were shown to mediate some of the
beneficial effects of CR on lifespan extension in part by boosting
cellular stress defense (Guarente, 2013). Overexpression of
Sirt1 in mice did not generally improve lifespan but resulted in
an increased healthspan (Herranz and Serrano, 2010). In
contrast, male (but not female) mice overexpressing Sirt6
showed a significant extension in lifespan (Kanfi et al., 2012).
Alternative pathways reported to promote longevity and
improve overall fitness include the overexpression of telome-
rase in the context of a cancer-resistant mouse (Toma´s-Loba
et al., 2008). Finally, several currently FDA-approved drugs
were also shown to increase lifespan in model organisms,
including the type II diabetes drug metformin (Cabreiro et al.,
2013; Martin-Montalvo et al., 2013) as well as several anticon-
vulsive agents (Evason et al., 2005). On the other hand, strate-
gies have also been developed that lead to decreased lifespan
and accelerated aging, such as impaired DNA repair by ATR
deficiency (Murga et al., 2009) or telomerase-null mice (Blasco
et al., 1997; Lee et al. 1998). An unresolved question remains
whether longevity pathways identified to date act exclusively
by slowing down the aging process or whether some of those
manipulations indeed achieve a true rejuvenation of previously
old cells. It will be interesting to revisit this question in the light
of the detailed cellular and molecular hallmarks of age available
(Lo´pez-Otı´n et al., 2013).
Another interesting toolset for studying the genetic drivers
of organismal aging is provided by animals with extraordinary
long or unusually short lifespan (Figure 1). For example, naked
mole rats have the body size of a mouse but a life expectancy
that is 10-fold higher, reaching more than 30 years of age in
captivity. Genetic studies are underway to define factors
responsible for such longevity in moles, bats, and other
long-lived animals (Kim et al., 2011a). Studies in hydra are
intriguing as an example of an organism that is short-lived
despite lacking evidence of cellular senescence. In conclu-
sion, the ability to modulate lifespan in model organisms as
well as the existence of extremely long- and short-lived or-
ganisms make a strong argument that aging might not simply
be the sum of accumulated damage throughout life but indi-
cate the existence of genetic programs affecting the rate of
aging.
Systemic Factors Affecting Age-Related Response
A key question in aging research is the relative contribution of
cell-autonomous versus non-autonomous, systemic factors
on age-related phenotypes. There has been renewed interestin this issue recently with the use of parabiosis. Parabiosis was
first described more than 150 years ago (Bert, 1864) and devel-
oped into a reliable technology for surgically linking the blood
circulation of two animals. Heterochronic parabiosis involves
linking animals of different age and has become an important
tool to study the impact of blood-derived factors present in
young animals on the age-dependent regenerative capacity of
old animals (Conboy et al., 2013) (Figure 1B). Those experiments
demonstrated improved regenerative potential of skeletal mus-
cle cells (Brack et al., 2007), improved neural precursor cell pro-
liferation, and cognitive function (Villeda et al., 2011) as well as
improved heart function (Loffredo et al., 2013) in old animals
following parabiosis with a young host. An important endeavor
has been the molecular identification of factors responsible for
this improved regenerative response. Several pathways have
been implicated including factors modulating Notch (Conboy
et al., 2005), WNT (Brack et al., 2007), or chemokine (Villeda
et al., 2011) signaling. There has been particular recent excite-
ment about the identification of the TGFb-ligandGDF11, capable
of enhancing regenerative responses across several tissues
including skeletal muscle, heart, and brain (Loffredo et al.,
2013; Sinha et al., 2014) (Figure 1B). The identification of
blood-derived factors presents a promising avenue for defining
candidate therapeutic targets that improve tissue regeneration.
One interesting point is the limited convergence of the results ob-
tained in parabiosis studies with those obtained in longevity
studies. In this light, it will be interesting to determine whether
improved regeneration through blood-borne molecules reflects
actual rejuvenation of the host tissue and whether long-term
manipulation of those pathways can extend lifespan. To this
end, it would be of particular interest to assess whether GDF11
or any other secreted factor can reset molecular hallmarks of ag-
ing or trigger improved regenerative responses independent of
cellular rejuvenation.
Cellular Hallmarks of Aging
There is no consensus on the specific molecular and biochem-
ical cause of organismal aging. Nevertheless, several candi-
date mechanisms have been proposed, ranging from cellular
processes like accumulation of genetic or epigenetic changes
to telomere shortening, mitochondrial dysfunction, or the accu-
mulation of damaged proteins to systemic age-dependent al-
terations such as deregulated nutrient sensing, impaired inter-
cellular communication, and the exhaustion of tissue-specific
stem cells (Lo´pez-Otı´n et al., 2013). Independently of whether
any of those candidate mechanisms are primary drivers of ag-
ing or mere side effects, they represent a set of molecular and
cellular hallmarks that can be used as surrogate markers to
measure cellular age across cell and tissue types. For the
scope of this review, we will focus on aging hallmarks that
manifest at the cellular level, which can provide simple quanti-
tative assays for measuring age in vitro (Figure 1C), though
other aging hallmarks such as deregulated nutrient sensing
and altered intracellular communication should be considered
as well. The use of a reliable marker platform is a prerequisite
for extending aging studies beyond organismal longevity or
tissue regeneration. In particular, it enables studies that
monitor the process of rejuvenation during iPSC induction
and facilitates ongoing efforts to induce age in iPSC-derived
lineages.Cell Stem Cell 16, June 4, 2015 ª2015 Elsevier Inc. 593
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Figure 2. Phenotypic Rejuvenation during
iPSC Induction
(A) Fibroblasts from an aged donor can be re-
programmed back to pluripotency and further
differentiated into iPSC-derived fibroblasts. During
this process, many cellular aging hallmarks are
reset to a young-like state ranging from cellular
senescence to nuclear morphology.
(B) Legend for each of the age-related hallmarks
reset during reprogramming.
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The ability to induce pluripotency in adult somatic cells has been
a major goal in biology. Somatic cell nuclear transfer (SCNT)
studies were first to demonstrate the feasibility of epigenetically
resetting a donor nucleus through transplantation into an enucle-
ated egg. Starting with the pioneering studies in the frog by Gur-
don (1962), many subsequent findings have confirmed that
SCNT can result in the birth of healthy animals derived from an
adult somatic cell nucleus. The most dramatic example for the
power of SCNT is represented by Dolly the sheep (Campbell
et al., 1996), whose birth immediately raised the question of
whether the process of epigenetic reprogramming had reset
the fate as well as the age of the original donor cell. Some initial
controversy on whether age was indeed reset after nuclear
transfer was based on analysis of telomere length in the cloned
animal. However, the premature death of Dolly was likely unre-
lated to incomplete rejuvenation, and most follow-up studies
indicate that telomere length is fully reset after nuclear transfer
(Lanza et al., 2000).
SCNT provided an initial proof-of-concept that it is possible to
reset the age-status of a somatic donor cell, but it did not yield a
tractable platform for routinely studying mechanisms of reprog-
ramming. The discovery of iPSCs by Shinya Yamanaka has been
the ‘‘game changer’’ required to make such studies feasible.
PSCs are characterized by the expression of pluripotency
markers, indefinite self-renewal, and their ability to contribute
to all the three germ layers of the embryo. However, many other
features of pluripotent stem cells, such as high telomerase activ-
ity, mitochondrial status, and aspects of their epigenetic state,
reflect features of young cells that are not restricted to the plurip-
otent state. Therefore, a key prediction is that the hallmarks of
cellular aging present in adult fibroblasts (e.g., short telomeres,594 Cell Stem Cell 16, June 4, 2015 ª2015 Elsevier Inc.loss of heterochromatin, and impaired
mitochondrial function) are reset during
iPSC induction. Indeed, bona fide iPSCs
are largely indistinguishable from ESCs
in the expression of age-related markers
such as telomere length (Marion et al.,
2009; Suhr et al., 2009) or mitochondrial
function (Prigione et al., 2011; Suhr
et al., 2010). However, adult somatic
cells, such as fibroblasts or adult blood-
derived lineages, are differentiated cell
types highly distinct from hPSCs. Thus,
a direct comparison of adult somatic cells
to their iPSC counterparts does not satis-
factorily address whether age-related
changes reflect a true rejuvenation orrather a simple switch in cell identity. Therefore, it was critical
to confirm whether iPSC-derived lineages, fate-matched to their
somatic equivalents, retain signs of rejuvenation. Initial studies in
iPSC-derived fibroblasts were focused on a limited set of hall-
marks that included mitochondrial stress response and cellular
senescence (Lapasset et al., 2011). We have recently reported
on the use of a more complete panel of age-associated cellular
markers suitable for reliably distinguishing fibroblasts derived
from young versus aged donors (Miller et al., 2013). Those
include: telomere length, mitochondrial function, DNA-damage
response, global loss of heterochromatin, nuclear lamina-asso-
ciated changes, and increase in the fraction of senescent cells.
Remarkably, every single age-related parameter expressed in
aged donor fibroblast population was reset after iPSC induction
and differentiation into iPSC-derived fibroblast-like cells (Miller
et al., 2013) (Figure 2). Another interesting case is the rejuvena-
tion of antigen-specific T cells following reprogramming into
T-cell-derived iPSCs and further differentiation into iPSC-
derived T cells (Nishimura et al., 2013; Themeli et al., 2013; Viz-
cardo et al., 2013). Such a strategy could counteract immune cell
exhaustion such as in the context of adoptive immunotherapy.
Despite clear evidence on phenotypic rejuvenation during re-
programming, several questions remain unsolved. For example,
in the case of reprogramming aged donor cells, it is possible that
rejuvenated iPSCs selectively arose from a small fraction of
phenotypically young cells within the original fibroblast popula-
tion. The use of clonal studies to address this point is chal-
lenging, given that fibroblast-derived clones may re-establish
heterogeneity of age-related marker expression. Hence, time-
lapse studies and use of real-time reporters for age-related
markers are needed to address the possibility of cellular selec-
tion during reprogramming. Another key question is whether
AB
Figure 3. Manipulating Cellular Age in
Pluripotent-Derived Cells
(A) The three stages of developmental timing: cell-
fate specification, maturation, and aging. In vitro
differentiation of hPSC to neuronal lineages fol-
lows a temporal program reminiscent of brain
development in vivo. PSC-derived neurons
commonly represent immature fetal-stage cells,
and novel tools are under development to improve
functional maturation and trigger expression of
age-related markers in pluripotent-derived cells.
(B) Modeling late-onset disorders in patient-spe-
cific cells may require the induction of stress or
age-related markers to uncover disease related
phenotypes. Most studies so far focused on
challenging cells with toxic stressors. We postu-
late that such paradigms are suitable to reveal
disease-related susceptibility phenotypes that
reflect early biochemical changes in the disease
process ‘‘early biochemical.’’ We propose
‘‘inducing aging’’ as an alternative strategy to
‘‘inducing stress’’ that may reveal additional dis-
ease phenotypes. As opposed to inducing stress,
strategies aimed at inducing age are thought to
trigger expression of the various molecular hall-
marks of age. Induced aging strategies draw
inspiration from naturally occurring mutations
known to cause premature aging, such as the
recently reported method based on the expres-
sion of progerin. An alternative strategy that has
not yet been implemented for human disease
modeling could involve the direct manipulation of
one or a subset of molecular hallmarks of aging
with the goal of eliciting cellular age in a more
physiological manner.
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plete reset of molecular markers of age. In particular, reports
suggest that cells retain epigenetic memory of age at the level
of DNA methylation (Kim et al., 2010; Kim et al., 2011b). It re-
mains to be determinedwhether suchmemory is indeed retained
over extended passages and can be reconciled with separate
findings on the rapid loss of epigenetic memory in iPSCs (Polo
et al., 2010).
Cellular Age in Pluripotent-Derived Cells
Directed Differentiation, Maturation,
and Age—Examples of the Nervous System
There has been extensive progress in the directed differentiation
of hPSCs to access a broad range of differentiated cell types. An
area of particular interest is the derivation of lineages of the CNS
for applications in regenerative medicine (Steinbeck and Studer,
2015) and human disease modeling (Bellin et al., 2012). Studies
in the nervous system also highlight some of the remaining chal-
lenges of directed differentiation, such as the protracted timing
of neuronal and glial fate specification, maturation, and age
(Figure 3A). From a chronological perspective, cell specification,
maturation, and aging represent contiguous temporal stages for
each cell type. However, the specific cellular processes and un-
derlying mechanisms characteristic of each stage are highly
distinct. Although acquisition of cell fate is characterized by spe-
cific transcriptional programs and marker expression, cell matu-
ration entails the development of functional features, such aselectrical activity and synaptic connectivity, in the case of
neuronal maturation. In contrast, aging is associated with a
gradual decline in neuronal structure and function. Hallmarks
of neuronal aging are often difficult to distinguish from disease-
related degenerative processes. A convenient age-related
marker is the pigment neuromelanin, which characterizes adult
and aged dopamine neurons in the midbrain but is absent in
matched cells at fetal and postnatal stages (Mann and Yates,
1974).
Challenges in neuronal fate specification include the genera-
tion of hPSC-derived cortical neurons. Current state-of-the-art
protocols require up to 100 days of differentiation to generate
upper layer cortical neurons (Espuny-Camacho et al., 2013; Shi
et al., 2012). Cortical interneurons subtypes such as parvalbu-
min (PV+) neurons require even more extended time lines of
in vitro or in vivo differentiation (Maroof et al., 2013; Nicholas
et al., 2013). Similarly, the generation of glial lineages such
as astrocytes (Krencik et al., 2011) or myelinating oligodendro-
cytes is highly protracted requiring differentiation periods
ranging from 3–6 months (Wang et al., 2013). Lengthy differen-
tiation protocols make hPSC studies laborious, costly, and
difficult to standardize. Transcriptome studies show that neural
human iPSC-derived tissues typically map with the first
trimester of human development (Mariani et al., 2012). Interest-
ingly, data obtained from 2D versus 3D organoid culture sys-
tems do not show major differences (Kadoshima et al., 2013;
Lancaster et al., 2013) suggesting that mimicking normal tissueCell Stem Cell 16, June 4, 2015 ª2015 Elsevier Inc. 595
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clock.
The timing of neuronal maturation presents additional chal-
lenges beyond cell fate specification. For example, grafted
hPSC-derived midbrain dopamine neurons require 4-5 months
of in vivo maturation to induce functional rescue in a rat model
of Parkinson’s disease (Kirkeby et al., 2012; Kriks et al., 2011).
Using the same xeno-transplantation paradigms but starting
with mouse ESC-derived DA neurons, behavioral recovery is
typically achieved in 4-5 weeks (Barberi et al., 2003; Kim et al.,
2002). Such species-specific differences in timing of dopamine
neuron maturation is mirrored in studies using primary, stage-
matched DA neurons from mouse, pig or human embryos (Isac-
son and Deacon, 1997). The most straightforward interpretation
of those studies is the presence of a species-specific, cell auton-
omous ‘‘clock’’ that controls the rate of maturation even when
exposed to the same host environment in the adult rodent brain.
Protracted maturation is also observed in midbrain dopamine
neurons in vitro as well as in many other neuronal cell types
such as peripheral sensory or cortical neurons. Interestingly,
cortical reprogramming strategies based on the use of lineage
specific transcription factors, show similar species-specific dif-
ferences in neuronal maturation between mouse and human
cells (Pang et al., 2011; Vierbuchen et al., 2010).
There has been some success in speeding up the timing of
neuronal cell-fate acquisition based on a combinatorial small-
molecule screen that resulted in the rapid induction of human
sensory neuron fates (Chambers et al., 2012). However, it re-
mains to be determined whether the same strategy is applicable
for the rapid derivation of other neuron types. Strategies for trig-
gering neuronal maturation have been even more challenging.
Improved cell-culture media formulations (Bardy et al., 2015)
and the use of astrocyte co-culture can accelerate electrophys-
iological maturation of hPSC-derived neurons. However, there is
no evidence that those conditions accelerate other aspects of
neuronal maturation, such as the acquisition of late-stage
neuronal markers including expression of parvalbumin (PV) in
cortical interneuron cultures. Interestingly, the induction of PV
was observed after co-culture of hPSC-derived interneurons
with mouse excitatory neurons (Maroof et al., 2013). Those
data suggest that activity and synaptic connectivity may
contribute to PV expression. One interesting alternative for
driving neuronal fate specification and maturation in hPSCs is
the ectopic overexpression of transcription factors such as
Ngn2 (Zhang et al., 2013). Under those conditions, hPSCs
rapidly adopt the fate of functionally active neurons. However,
full maturation of those neurons remains a challenge, and it re-
mains unclear whether those Ngn2-induced neurons reflect a
relevant human neuron subtype or an artificial neuron without a
direct counterpart in the human brain. Therefore, better strate-
gies are needed to trigger the maturation of hPSC-derived line-
ages in the CNS and beyond.
Disease Modeling via iPSCs
Human iPSC technology represents a powerful tool for both
mechanistic studies and therapeutic development in human ge-
netic disorders. Differences in patient-specific versus control
iPSC-derived cells are defined as candidate disease pheno-
types. However, the choice of the appropriate control iPSC lines
for such studies is challenging given genetic heterogeneity in the596 Cell Stem Cell 16, June 4, 2015 ª2015 Elsevier Inc.general population. The use of isogenic, gene-corrected lines
can increase confidence in the specificity of disease pheno-
types. A major challenge remains the demonstration that a given
phenotype is indeed disease-relevant, a process that may
include lengthy follow-up studies in model organisms or relevant
patient tissues. Over the past few years, there has been an
increasing body of work reporting on disease-related pheno-
types in patient-specific iPSCs (Bellin et al., 2012). In a much
smaller set of studies iPSC-based disease modeling efforts
have moved beyond the identification of disease phenotypes to-
ward novel mechanistic insights. Examples from our team
include themodeling of tissue-specific splicing defects in familial
dysautonomia (FD) (Lee et al., 2009) or the cell-type-specific de-
fects in innate immunity in the case of primary herpes simplex
encephalitis (HSE) (Lafaille et al., 2012). There has also been suc-
cess in using iPSC-based models for drug discovery (Lee et al.,
2012), including studies wherein hit compounds have now
moved forward into early-stage clinical trials, such as kinetin in
the case of FD, the anticonvulsant compound retigabine for the
treatment of amyotrophic lateral sclerosis (ALS) (Wainger et al.,
2014), or IGF-1 in the treatment of autism-related disorders (Mar-
chetto et al., 2010),(Shcheglovitov et al., 2013).
Many labs are pursuing iPSC-based disease modeling, and
thousands of patient-specific iPSC lines are currently under pro-
duction across the globe. In contrast, there is a much more
limited effort to address remaining limitations of the technology.
One such challenge is the question of how to introduce ‘‘age’’
into iPSC-based models of late-onset disorders. It is well known
that age is the largest risk factor for many human disorders
ranging fromADand PD to cancer, trumping the combined effect
of both environment and genetics (Niccoli and Partridge, 2012).
Most current iPSC studies model late-onset disease phenotypes
in iPSC-derived neurons that represent first-trimester-stage
cells. Despite such an age mismatch, some studies have suc-
cessfully modeled aspects of human disease including AD and
PD (reviewed in Liu et al. [2012a] and Srikanth and Young-Pearse
[2014]). One interpretation is that such studies model suscepti-
bility rather than normal disease or disease progression.
Modeling disease susceptibility can be very powerful for study-
ing biochemical changes directly dependent on a genetic defect.
For example, changes in amyloid precursor protein processing,
a-synuclein accumulation, or mitochondrial function have been
reported in models of AD or PD.
Induced Aging Strategies
The most common strategy to induce age-like features in iPSC-
derived lineages is the use of stress paradigms. Various studies
have modeled late onset disorders in iPSC-derived cells
following exposure to toxins, including compounds that trigger
mitochondrial stress or ROS (Byers et al., 2011; Cooper et al.,
2012; Liu et al., 2012b; Nguyen et al., 2011; Reinhardt et al.,
2013; Seibler et al., 2011). Such in vitro stress paradigms may
uncover disease-related susceptibility phenotypes (Figure 3B).
However, it remains to be determined whether stressing
‘‘young’’ cells appropriately mimics age-related disease suscep-
tibility. For example, it may be equally important to understand
the nature of the protective mechanisms that stave off disease
rather than to artificially force a disease phenotype in ‘‘young’’
cells. Another key concern is that most diseasemodeling studies
have not assessed the impact of stress paradigms on the
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ideal in vitro aging strategy involves the induction of age-related
hallmarks in both healthy and patient-specific cells without ex-
erting overt toxicity. In vitro aging paradigms should be a tool
for measuring the contribution of age-related changes and
studying the interaction of genetic (isogenic lines) and age-
related susceptibility on disease phenotypes.
Alternative strategies to manipulate cellular age in iPSC-
derived lineages include insights frompremature aging disorders
such as Hutchinson Gildford progeria syndrome (HGPS), dys-
keratosis congenita, and Werner and Cockayne syndrome,
among others (Kipling et al., 2004). Interestingly, iPSC models
of those progeroid syndromes show in large a reset of age-
related phenotypes upon reprogramming followed by a rapid re-
acquisition of age-like features upon differentiation (Agarwal
et al., 2010; Andrade et al., 2012; Batista et al., 2011; Liu et al.,
2011; Zhang et al., 2011). These findings indicate that the induc-
tion of cellular age markers should be achievable by ectopically
expressing progeroid gene products in wild-type iPSC-derived
cells. In agreement with this, a recent report describes how de
novo expression of mutant Werner syndrome gene in human-
ESC-derived cells drives the appearance of cellular aging hall-
marks, such as alterations in heterochromatin organization
(Zhang et al., 2015). We previously reported ectopic expression
of progerin, the mutant gene product causing HGPS, as a strat-
egy to induce age-related hallmarks in iPSC-derived fibroblasts
and neurons (Miller et al., 2013) (Figure 3B). We used the strategy
to identify age- and disease-associated phenotypes in PD-iPSC-
derived dopamine neurons. Among the most dramatic age-
related phenotypes was the accumulation of neuromelanin,
which is an age-related marker of midbrain dopamine neurons.
Other findings included the presence of pathological intracellular
structures by electron microscopy and the progressive loss of
tyrosine-hydroxylase-positive cells after transplantation, pheno-
types that required the interaction of genetic (Parkin mutation)
and age-related susceptibility (progerin exposure). A key feature
of the approach is the ability to ectopically drive progerin expres-
sion in iPSC-derived neurons of any genetic background, as
endogenous progerin levels in HGPS-iPSC-derived neurons
are likely too low for triggering age-related neuronal phenotypes.
In fact, neurons appear largely spared in HGPS patients. This rai-
ses the question of how closely progerin exposure mimics
normal aging. We demonstrate that progerin expression can
induce phenotypic hallmarks of aging in iPSC-derived lineages,
including neurons. However, beyond those phenotypic studies,
we have not yet analyzed in-depth the molecular changes asso-
ciated with progerin exposure. Therefore, it is conceivable that
progerin may trigger age-relatedmarkers via a distinct molecular
mechanism in comparison to normal aging.
Future strategies to induce aging may move beyond
mimicking human progeroid disorders toward applying the
increasing mechanistic understanding of human aging. The
direct manipulation of any of the key cellular and molecular hall-
marks of aging may be a particularly promising approach. Effi-
cient tools for genome editing, such as the CRISPR/Cas9
system, will greatly facilitate such efforts and enable the system-
atic targeting of candidate pathways alone or in combination.
The question whether manipulation of a single pathway can
trigger broader changes in age-related hallmarks will be particu-larly important. Furthermore, it will be interesting to assess
whether any given induced aging strategy may be more appro-
priate for a specific cell or tissue type (e.g., proliferating versus
postmitotic tissue). Such efforts could go hand in hand with
studies in model organisms. For example, recent efforts to sys-
tematically manipulate hallmarks of aging in the short-lived
African killifish (Harel et al., 2015) using CRISPR/Cas9 technol-
ogy could be highly complementary in determining the impact
of aging strategies on individual organs.
Conclusions
We propose PSCs cells as a novel model for studying human ag-
ing. Unlike traditional aging paradigms that focus on endpoints
such as longevity or the restoration of regenerative capacity,
PSCs allow us to monitor and manipulate molecular and cellular
hallmarks of aging during both reprogramming and cell differen-
tiation. Capturing the timing and sequence of the steps involved
in cellular rejuvenation offers a unique opportunity for subse-
quent mechanistic studies. The strong evidence for cellular reju-
venation during iPSC induction indicates that many aspects of
aging are reversible and may represent epigenetic rather than
genetic barriers in biology. Therefore, a future is conceivable
wherein it will be possible to reliably rejuvenate somatic cells
without the need to move them back to pluripotency. In addition
to studying rejuvenation, it will be equally important to identify
novel induced aging strategies. The ability to direct both cell
fate and age in iPSC-derived lineages will allow modeling of hu-
man disorders at unprecedented precision. Such studies could
yieldmore relevant disease phenotypes and define novel classes
of therapeutic compounds targeting age-related cell behaviors.
The ability to program and reprogram cellular age on demand
will present an important step forward on the road to decoding
the mystery of aging.
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